dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· November 27, 2025

BioNTech (BNTX) Q3 2025 Earnings Call Transcript

View original at nasdaq.com
BioNTech (BNTX) Q3 2025 Earnings Call Transcript Image source: The Motley Fool. Date Nov. 3, 2025 at 12:46 p.m…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We expect to report a loss for the 2025 financial year as we continue to invest in our transition to become a fully integrated commercial oncology company

    80% confidence

  • First potential launches of Pumitamig expected before end of decade (pre-2030)

    80% confidence

  • T-cell response breadth correlates with activity in iNeST therapy; immune cell PD-L1 matters; signal observed in TMB-low patients

    80% confidence

  • US COVID-19 vaccination rate at ~20% is in line with expectations

    80% confidence

  • COVID-19 vaccine business has stable market share and pricing with lower volumes vs prior year, performing within expectations

    80% confidence

  • First pivotal combination regimen decisions for Pumitamig expected based on data over next year

    80% confidence

  • Management emphasized rigorous financial discipline and focus on long-term sustainable growth

    80% confidence

  • BioNTech is positioned as a fully integrated AI-tech bio company with AI capabilities addressing inter-patient heterogeneity and intra-tumor variability

    80% confidence

Data points we hold from this source

BioNTech SE · eps-0.12 EUR
BioNTech SE · net income-29 million_EUR
BioNTech SE · rd expenses565 million_EUR
BioNTech SE · sga expenses148 million_EUR
BioNTech SE · cost of sales148 million_EUR

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
BioNTech (BNTX) Q3 2025 Earnings Call Transcript: Source | Via News | fr.via.news